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Background: Combination therapy, which reduces the dosage intensity of the individual drugs while increasing their
efficacy, is not a novel approach for the treatment of cancer. Methylsulfonylmethane (MSM) is an organic sulfur compound
shown to act against tumor cells. Tamoxifen is a commercially available therapeutic agent for breast malignancies.
Methods: In the current study, we analyzed the combinatorial effect of MSM and tamoxifen on the suppression of
ER-positive breast cancer xenograft growth and metastasis. Additionally, we also validated the molecular targets by which
the drug combination regulated tumor growth and metastasis.
Results: We observed that the combination of MSM and tamoxifen regulated cell viability and migration in vitro. The
intragastric administration of MSM and subcutaneous implantation of tamoxifen tablets led to tumor growth suppression
and inhibition of the Janus kinase 2 (Jak2)/signal transducer and activator of transcription 5b (STAT5b) pathway. Our
study also assessed the regulation of signaling molecules implicated in the growth, progression, differentiation, and
migration of cancer cells, such as Jak2, STAT5b, insulin-like growth factor-1Rβ, and their phosphorylation status.
Conclusions: Study results indicated that this combination therapy inhibited tumor growth and metastasis. Therefore,
this drug combination may have a synergistic and powerful anticancer effect against breast cancer.
Keywords: Breast cancer, Methylsulfonylmethane, Tamoxifen, Jak2/STAT5b pathway, Xenograft, MetastasisBackground
Breast cancer (BCa) is one of the most common cancer
in women across the world with the second highest rate
of mortality each year [1, 2]. Recent studies have proven
that environmental factors play a vital role in the incidence
of BCa [3]. Cell proliferation and apoptosis regulates the
development of cancer, and these two mechanisms are* Correspondence: ymyang@kku.ac.kr
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agents [4].
Janus kinase (Jak), signal transducer and activator of
transcription (STAT), and insulin-like growth factor
(IGF) are the major genes overexpressed in breast cancer
[5]. Upon cytokinebinding to the receptors, Jak tyrosine
kinases phosphorylate specific tyrosine residues in the
receptors, which then act as docking sites for the STAT
family of transcription factors [6]. The STAT family con-
sists of seven different transcription factors that play
crucial roles in cytokine signaling [7]. STAT5b, an im-
portant member of the STAT family, is activated by
phosphorylation, dimerizes, and then translocates to thedistributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
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Sequence (5’ - 3’)
1 Cyclin-D1 58 135 F – gctgcgaagtggaaaccatc
R – cctccttctgcacacatttgaa
2 IGF-1Rβ 58 522 F – actatgccggtgtctgtgtg
R – tgcaagttctgattgttgag
3 IGF-1 58 498 F – tcctcgcatctcttctacct
R – tctggactcgccagtccaat
4 VEGF 58 405 F – aggagggcagaatcatcacg
R – caaggcccacagggattttc
5 18S 58 490 F –
agccttcggctgactggctgg
R – ctgcccatcatcatgacctgg
6 MMP2 53 665 F – gagttggcagtgcaatacct
R – gccatccttctcaaagttgt
7 MMP3 60 432 F – cctgctttgtcctttgatgc
R – tgagtcaatccctggaaagt




60 700 F – tggcatgttttgaggttttg
R – gattggttgtgtggcatgag
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directly regulates the expression of target genes [8, 9].
IGF-1, IGF-1Rβ, and cyclin D1 are the main downstream
targets of STAT5b [10, 11]. IGF-1Rβ is a transmembrane
tyrosine kinase that participates in cell proliferation and
apoptosis. Due to its influence on invasion and metasta-
sis, IGF-1Rβ is considered to be an anticancer treatment
target [12].
The estrogen receptor (ER) has been shown to be of
prognostic significance for BCa patients. More import-
antly, ER can be a predictive marker for endocrine therapy
in the clinical management of BCa [13, 14]. Tamoxifen
(Tam) is a selective ER modulator that can act as either an
ER agonist or antagonist, and is a synthetic, non-steroidal
compound used for the treatment of ERα-positive and
other hormonally-responsive BCa [15]. Tam acts by con-
trolling the binding of estradiol to the ER and forms a
tam-ER complex which then binds to DNA. This leads to
the failure of transcriptional activation and growth inhib-
ition in estrogen-dependent cells [16].
Research efforts to find natural compounds for tumor
growth suppression have revealed great potency and
potential in cancer management. Methylsulfonylmethane
(MSM), also known as dimethyl sulfone, is an organic
sulfur compound mainly present in foods such as fruits
and vegetables, and in beverages as well. Therefore, MSMintake is possible through diet [17–19]. Study results have
demonstrated that MSM was associated with antioxidant
and anti-inflammatory mechanisms [20, 21]. The pharma-
cokinetics studies on MSM indicated that, uptake and dis-
tribution of MSM throughout the body rapidly and it was
eliminated through the urine [22, 23]. The studies related
with high dosage of oral administration of MSM showed
the upregulated levels of MSM in blood which indicating
the ability of MSM to diffuse in blood even in high con-
centration [24, 25]. Recently, we suggested that MSM
could substantially decrease the viability of human BCa
cells due to its anticancer activities, such as contact inhib-
ition, wound healing, and blockage of cell migration
[10, 26]. Additionally, Caron et al. reported that MSM man-
ifests anti-cancer activity in metastatic BCa cells [27, 28].
Combination therapy is not a new approach for the
treatment of cancer. Its purpose is to reduce the dose in-
tensity in order to mitigate toxicity while increasing the
efficacy of the drugs. Our principal aim was to develop a
new drug combination that could be more effective with
less, or no, toxicity by altering drug concentrations.
MSM has the ability to inhibit STAT3 and STAT5b in
human breast cancer cell lines [10]. Tam has already
found out to be an anti-cancer drug used in the combin-
ation therapy [29–31]. It can also synergize the efficacy
of other drug in the combination therapy [32–34]. So in
the current study, we hypothesized that the combination
of MSM and Tam could synergize the anti-BCa effects
of tam at an even milder dose, owing to the ability of
MSM to inhibit the STAT5b and STAT3 signalling path-
ways. Such a drug combination may have the ability to




Human breast adenocarcinoma, MCF-7, and T47D cell
lines were purchased from South Korean Cell Bank
(Seoul, KR). RPMI-1640 was purchased from Sigma
Chemical (St. Louis, MO, USA). Penicillin-streptomycin
solution and fetal bovine serum (FBS) were purchased
from Hyclone (South of Logan, Utah, USA). 0.05 %
trypsin-ethylenediaminetetraacetic acid was purchased
from Gibco-BRL (Grand Island, NY, USA). STAT5b, vas-
cular endothelial growth factor (VEGF), VEGF-R2, IGF-
1Rβ, matrix metalloproteinase (MMP)2, MMP3, MMP9
antibodies, and secondary antibodies (goat anti-mouse
and rabbit immunoglobulin G [IgG]-horseradish perox-
idase) were obtained from Santa Cruz Biotechnology
(Santa Cruz, CA, USA). Jak2 was obtained from Millipore
(Billerica, MA, USA). Phosphorylated Jak2 antibody were
purchased from Cell Signalling Technology (Beverly, MA,
USA), and phosphorylated STAT5 was purchased from
Upstate Biotechnology (Lake Placid, NY, USA). β-actin
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USA). The enhanced chemiluminescence (ECL Plus) de-
tection kit was purchased from Amersham Pharmacia
Biotech (Piscataway, NJ, USA). Restore™ Western Blot
Stripping Buffer and NE-PER kits were purchased from
Pierce (Rockford, IL, USA). RNeasy mini kits and Qiaprep
spin miniprep kits were purchased from Qiagen (Hilden,
Germany). Reverse transcriptase-polymerase chain reac-
tion (RT-PCR) premix kits and VEGF, IGF-1, IGF-1Rβ,
cyclin D1, MMP2, MMP3, MMP9, 18 s primers for
RT-PCR were synthesized by Bioneer (Daejon, Korea).
Electrophoretic mobility shift assay (EMSA) kits and
oligonucleotide probes (STAT5b) were obtained from
Promega Corp (Madison, WI, USA). Paraformaldehyde
and mounting solution for immunohistochemistry were
purchased from Dae Jung Chemicals & Metals Co.
(Shineung-city, Korea) and Life Science (Mukilteo, WA,
USA). Imprint chromatin immunoprecipitation assay
kits, Triton X-100, and tamoxifen were obtained from
Sigma Chemical Co. (St. Louis, MO, USA). MSM was
purchased from Fluka/Sigma Co. (St. Louis, MO, USA).
17β-estradiol pellets (0.72 mg, 60 days release) and tam-
oxifen tablets (0.72 mg, 60 days release) were purchased
from Innovative Research of America (Sarasota, FL, USA).
Ethics statement
All procedures for animal experiments were approved by
the Committee on the Use and Care on Animals, (Institu-
tional Animal Care and Use Committee, Seoul, Korea) and
performed in accordance with the institional guidelines.
Cell culture and treatment
MCF-7, and T47D cell lines were maintained in RPMI-
1640 medium containing 10 % FBS, 100U/mL penicillin
and streptomycin at 37 °C in 5 % CO2. The cells were
placed in airtight chambers (Nu Aire, Plymouth, MN,
USA). At the beginning of each experiment, the cells
were resuspended in the medium at a density of 2.5 ×
105 cells/mL. Cells were treated with Tam at 25 μM,
MSM at 300 mM and/or a combination of both (Tam at
15 μM and MSM at 200 mM).
Cell proliferation inhibition
Cell viability was assayed by measuring blue formazan
that was metabolized from 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyl tetra-zolium bromide (MTT) by mitochon-
drial dehydrogenase, which is only active in live cells. The
cells were resuspended in the medium one day before
drug treatment, at a density of 3 × 103 cells per well in
96-well culture plates. Liquid medium was replaced with
fresh medium containing dimethyl sulfoxide (DMSO) for
control (vehicle). Cells were incubated with various
concentrations of Tam, MSM, and their combinations
(1:10000, 3:40000). MTT (5 mg/mL) was added to eachwell and incubated for 4 h at 37 °C. The formazan product
formed was dissolved by adding 200 μl DMSO to each
well, and the absorbance was measured at 550 nm on
an Ultra Multifunctional Microplate Reader (TECAN,
Durham, NC, USA). All measurements were performed in
triplicate, and were repeated at least three times.
Apoptosis analysis
Fluorescein-conjugated annexin V (annexin V-FITC) was
used to quantitatively determine the percentage of cells
undergoing apoptosis. Drug-treated cells were washed and
resuspended in binding buffer at a concentration of 1 ×
106 cells/mL. The cells undergoing apoptosis were stained
with annexin V-FITC and propidium iodide. After incu-
bation for 15 min at room temperature in the dark, the
percentage of apoptotic cells was analyzed using flow
cytometry (Becton-Dickinson FACScan, San Jose, CA,
USA). 10 μM camptothecin was used as the positive con-
trol for the analysis.
Western blotting
The MCF-7 and T47D cell lines were treated with Tam,
MSM, and their combination for predetermined periods
of time. Whole cells were lysed on ice with radioimmu-
noprecipitation lysis buffer containing phosphatase and
protease inhibitors. Cells were disrupted by aspiration
through a 23-gauge needle, and centrifuged at 15,000 rpm
for 10 min at 4 °C to remove cellular debris. Protein con-
centrations were measured using the Bradford method.
Equal amounts of proteins were resolved on sodium dode-
cyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE)
and transferred onto nitrocellulose membrane. The blots
were blocked for 1 h with 5 % skim milk. Membranes were
probed over night at 4 °C with a primary antibody
followed by HRP-conjugated secondary antibodies. Detec-
tion was performed using the ECL Plus detection kit and
an LAS-4000 imaging device (Fujifilm, Japan).
Apoptotic DNA ladder analysis
The MCF-7 and T47D cell lines were treated with Tam,
MSM, and their combination for 24 h. The cells were
then collected by centrifugation, and DNA ladder ana-
lyses were carried out using DNA ladder kits. The DNAs
were isolated as per kit protocol and products were then
analyzed by electrophoresis with 1 % agarose gel con-
taining ethidium bromide. Lyophilized apoptosis U937
cells were used as a positive control.
RT-PCR
Total RNAs were extracted using RNeasy Mini Kits
(Qiagen) and quantified spectrometrically at 260 nm.
RT-PCR analysis for IGF-1, IGF-1R, cyclin D1, VEGF,
and 18 s RNAs were then performed. cDNA was synthe-
sized from total RNA by RT at 42 °C for 1 h and 80 °C
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neer, Korea). PCR was conducted using cDNA. The PCR
conditions consisted of denaturation for 30 s–1 min at
94–95 °C, annealing for 30 s–1 min at 55–60 °C, and ex-
tension for 30 s–1 min at 72 °C. PCR products were ana-
lyzed by 1 % agarose gel stained with ethidium bromide.
EMSA
The DNA binding activity of STAT5b was assessed using
EMSA, in which a labeled double-stranded DNA was
used as a DNA probe to bind active STAT5b proteins in
nuclear extracts. Nuclear protein extracts were prepared
with a nuclear extract kit (Panomics, AY2002). The
EMSA experiment was performed by incubating a
biotin-labeled transcription factor-STAT5b probe with
treated and untreated nuclear extracts. Proteins were re-
solved on a non-denaturing 6 % PAGE gel (Bio-Rad,
Korea). The proteins in the gel, transferred to a nylon
membrane and detected using streptavidin-HRP and a
chemiluminescent substrate.
Chromatin immunoprecipitation assay (ChIP)
A ChIP assay was performed using an Imprint Chroma-
tin Immunoprecipitation Kit (Sigma, St. Louis, MO,
USA) according to the manufactures protocol. Briefly,
MCF-7 cells were fixed with 1 % formaldehyde and
quenched with 1.25 M glycine. After washing with PBS,
the cells were suspended in nuclei preparation buffer
and shearing buffer, and sonicated under optimized con-
ditions. This sheared DNA was then centrifuged and a
cleared supernatant was used for protein/DNA immuno-
precipitation. The clarified supernatant was diluted with
dilution buffer (1:1 ratio) and 5 μl of diluted samples
were removed as an internal control. The diluted super-
natant was incubated with antibody (STAT5b) in pre-
coated wells for 90 min. For negative and positive con-
trol, normal mouse IgG and anti-RNA polymerase II
were used, respectively. The unbound DNA was washed
off with IP wash buffer and the bound DNA was col-
lected by cross link reversal using DNA release buffer
containing proteinase K. The released DNAs and the
DNA from the internal controls were purified with Gen-
Elute Binding Column G. The DNA was then quantified
using conventional PCR.
Wound healing assay
MCF-7 cells were cultured in 6-well plates at a concen-
tration of 1 × 105 cells/well in RPMI-1640 media and
incubated for 24 h in a humidified chamber. After be-
coming a confluent monolayer, the cell layers were
scratched with a pipette tip and washed with PBS to re-
move cell debris. Cells were treated with the required
concentrations of drugs (Tam, MSM, and their combin-
ation). Control cells were not treated. Wound edgeswere photographed at different time intervals using
a microscope. The relative area of wound closure was
measured using ImageJ software [35] (NIH Image, Bethesda,
MD, USA).
Matrigel invasion assay
The transwell invasion assay was performed with the
help of Matrigel pre-coated, ready to use invasion cham-
bers (BD Biocoat, MA, USA). Cells suspended at 5 × 104
were added to the inserts. The drug-containing media
was added to the receiver plate and the inserts were
placed onto it. After a 24 h incubation in a humidified
chamber at 37 °C, the cells that invaded to the apical
surface of the inserts were resolved with crystal violet.
The cells on the upper surface were removed using a
cotton swab and the invaded cells were observed using a
microscope. Focus was placed on four distinct areas and
the cells were counted.
Small interference RNA (siRNA) analysis
T47D cells (1 × 105) were cultured on 6-well plates and
grown to 50 % confluence. The cells were then trans-
fected with ON-TARGET plus SMARTpool siRNA tar-
geting STAT5b or ON-TARGETplus non-targeting
siRNA (Dharmacon, Chicago, IL, USA) using Fugene 6
(Roche, IN, USA) according to the manufacturer’s in-
structions. Following transfection with this mixture for
24 h, invasion assays were conducted without adding
drugs for an additional 24 h. Different areas were cap-
tured and the cells were counted.
Tumorigenecity
All procedures for animal experiments were approved by
the Committee on the Use and Care of Animals (Institu-
tional Animal Care and Use Committee, Seoul, Korea)
and performed in accordance with institutional guide-
lines. For the establishment of ER–positive MCF-7 xeno-
grafts, mice were ovariectomized and a 17β-estradiol
pellet (0.72 mg, 60 days release; Innovative Research of
America, Sarasota, FL, USA) was implanted subcutane-
ously into the neck to facilitate optimal tumor growth.
The xenografts were initiated by subcutaneously inject-
ing MCF-7 cells (1 × 107) into the flank of the right hind
leg. When tumors reached between 6–8 mm in diam-
eter, 6 mice were randomly assigned to one of four
groups: control, Tam, MSM, or their combination. For
the MSM-treated group, 3 % MSM was administered as
an intragastric injection of 100 μl with triple distilled
water. For the Tam-treated group, a Tam pellet (0.72 mg,
60 days release; Innovative Research of America) was
implanted subcutaneously into the neck. For the
combination-treated group, a Tam pellet was implanted
on the neck and MSM was administered as an intragas-
tric injection. The injections were repeated one time per
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surements with digital calipers. When the diameter of
tumors reached 2 cm, or after 30 days of treatment, the
animals were sacrificed. In our experiments, no mice
were observed to be dying due to tumor loading. All
available BCa specimens collected from human BCa
xenograft mice were reviewed and included in the
study. Mice were euthanized and tumors were re-
moved. The tumors were fixed with 4 % paraformalde-
hyde followed by paraffin embedding and sectioning
(5 mm). The sections were stained with hematoxylin
and eosin (H&E).
Metastatic animal models
Orthotopic metastatic animal models were induced by
tail vein injection of MCF-7 cells into 5-week-old BALB/
c nude mice (Orient Bio, Korea). For inducing tumors in
the MCF-7 model, mice were overiectomized and im-
planted with a 17β-estradiol pellet subcutaneously into
the neck. The mice were randomly devided into four
goups and treatment was administered as in the xeno-
graft animal model. A Tam pellet was also subcutane-
ously injected into the neck along with 17β-estradiol.
The control group was treated with vehicle, and for the
MSM-treated group, 300 mM MSM was administered as
a 100 μl intragastric injection. The combination group
was treated with 300 mM MSM and a Tam pellet. Treat-
ment was given for 30 days, at which time the mice were
sacrificed. Lungs were removed, fixed in 10 % formalin,
and paraffin embedded. The analysis of the tissue was
performed with the help of H&E staining. The numbers
of metastatic tumors on the lung were counted and the
relative inhibition of metastatsis was determined.
H&E staining
Consecutive sections (5 μm thick) were made using the
formalin-fixed xenografts and lungs embedded in paraf-
fin. Sections were then deparaffinized and rehydrated
with xylene, followed by washing in a decreasing gradi-
ent of ethanols (100 %, 95 %, 90 %, 80 %, and 70 %) and
staining with H&E. The slides were observed under a
microscope and photographed.
Immunoflurescence (IF)
Formalin-fixed paraffin-embedded breast tumor xeno-
grafts were deparaffinized with 100 % xylene, rehydrated
in a decreasing gradient of ethanols, permeabilised with
0.1 % triton X-100, and blocked with 10 % normal goat
serum in PBS. These were then incubated with the
STAT5b or IGF-1Rβ primary antibodies, followed by
incubation with the appropriate secondary antibody,
Alexa Fluor 594 (rabbit) and Alexa Fluor 488 (mouse)
(Invitrogen, CA, USA). For the detection of the nucleus,
tissue sections were incubated with fluorochrome 4’-6-diamidino-2-phenylindole for one minute and rinsed with
PBS. Samples were observed and photographed under a
fluorescent microscope.
Synergy quantification and statistical analysis
The synergy induced by the drug combination was ana-
lyzed with the use of Compusyn software. Combination
index (CI) values were computed based on the method
of Chou and Talalay [36]. CI computation values to be
interpreted as CI > 1 additive effect CI < 1 synergism. All
experiments were repeated three times and the results
are expressed as mean ± SEM. Statistical analyses were
conducted using student’s t -tests or ANOVA tests with
the SAS program.
Results
Synergistic inhibition of cell proliferation by the
combination of tamoxifen and MSM
To determine the level of inhibition of human breast
adenocarcinoma cell line proliferation mediated by
MSM, Tam, and their different combinations, the number
of treated cells during the logarithmic phase was compared
with that of the non treated control cells. Cell growth was
inhibited by ~40 % with 25 μM Tam and ~45 % with
300 mM MSM after 24 h of treatment (Fig. 1a). These
concentrations were then used for further experiments.
For obtaining the synergic combination dosage, different
proportions (1:10000 and 3:40000) of Tam and MSM were
used randomly. Compusyn analysis of proliferation inhib-
ition data showed that the combination of Tam and MSM
at the 3:40000 ratio had a synergistic effect below Fa = 0.68
(Additional file 1: Table S1). The IC50 dosage determined
by Compusyn for the combination was 198.619 mM of
MSM and 14.9 μM of Tam. This combination showed
a synergistic effect with a CI value of 0.51. Therefore,
we employed 200 mM of MSM and 15 μM of Tam as
the combination concentration for further experiments
(Fig. 1b).
The combination of tamoxifen and MSM induced
apoptosis in MCF-7 cells
The proliferation inhibition assay demonstrated that the
combination could induce growth arrest. Our next aim
was to detect the ability of the combination to induce
apoptosis. For detecting and quantifying the cells under-
going apoptosis, we performed annexin V-FITC flow
cytometry (Fig. 1c). The cells undergoing necrotic death
were counter stained with propidium iodide. 10 μM
camptothecin served as a positive control. The obtained
results showed that the combination had a stronger
ability to induce apoptosis (46 %) than the individual
values of Tam (30 %) and MSM (38 %) even though
the concentrations of the individual drugs in the
combination were lower. An increased Bax expression
Fig. 1 Synergistic inhibition of cell proliferation by the combination of Tam and MSM and induction of apoptosis. (a) 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyl tetra-zolium bromide assay for cell proliferation arrest by Tam, MSM, and their combinations in MCF-7 breast cancer cells. (b) Com-
bination index plot for drug combination and table for various concentrations of Tam and MSM by Compusyn. (c) Apoptosis induced using MSM,
Tam, or the combination in MCF-7 cells quantified using flow cytometry. Camptothecin was used as positive control. (d) Western blotting analysis
of Bax protein levels in MCF-7 and T47D cells, and after treatment with Tam, MSM, or their combination for 24 h. (e) Graphical representation of Bax
protein levels in MCF-7 and T47D cells, and after treatment with Tam, MSM, or their combination for 24 h
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apoptosis by the drug combination (Fig. 1d). Our drug
combination gave a significant up-regulation of Bax
level in total proteins (Fig. 1e). The pro-apoptotic ability
of our drug combinations was confirmed by a DNA
ladder assay in ER-positive BCa cells (Additional file 2:
Figure S1).
The combination of MSM and tamoxifen synergistically
inhibited the Jak2/STAT5b pathway
The expression levels of different proteins involved in
the Jak2/STAT pathway were analyzed by western blotting.
As seen in Fig. 2a, combination treatment synergistically
inhibited the expression, as well as the phosphorylation,
of the Jak2/STAT pathway constituents (Jak2, STAT3,STAT5b, and IGF-1Rβ) in MCF-7 and T47D cells. The
combination of Tam and MSM gave an evident result to
prove our hypothesis by showing that the levels of expres-
sion being downregulated occurred in the setting of the
steady expression of the loading control (β actin). This
result indicated that Tam and MSM suppressed Jak2,
STAT3, STAT5b, and IGF-1Rβ whereas its combination
gave more inhibition than individual concentration in both
MCF-7 and T47D cells. The densitometrical analysis of
Fig. 2a proved the ability of drug combination to down-
regulate the tumor proteins (Additional file 3: Figure S2a).
In both cell types, however, the signalling molecules were
more severely inhibited by the drug combination, even
though the concentrations of Tam or MSM in combin-
ation were lower.
Fig. 2 Combination MSM-Tam treatment synergistically inhibited the Jak2/STAT5b signaling pathway. (a) Western blotting analysis of cytoplasmic
protein levels in MCF-7 and T47D cells, and after treatment with Tam, MSM, or their combination for 24 h. (b) Nuclear protein level analysis in MCF-7
and T47D cells, and after treatment with Tam, MSM, or the drug combination for 24 h using western blotting. (c) The DNA binding activity of STAT5b
was inhibited by the drug combination, as analyzed by a gel shift assay in MCF-7 cells. (d) The DNA binding activity of STAT5b was inhibited by the drug
combination and confirmed by a ChIP assay in MCF-7 cells. Statistical analyses were conducted using the ANOVA test (**P < 0.01 and ***P < 0.001)
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the drug combination
Phosphorylated STAT3 and STAT5b should be translo-
cated to the nucleus to perform their transcriptional
regulation functions. Nuclear translocation was studied
using nuclear extracts isolated from MCF-7 and T47D
cells pretreated with the combination and the individual
agents separately. The western blotting analysis of the
nuclear extracts showed a marked decrease in total and
phospho STAT5, STAT3, and IGF-1Rβ levels (Fig. 2b)
in the combination-treated group as compared to
the groups with individual agents (Additional file 3:
Figure S2b). The DNA binding activities analyzed using
EMSA were confirmed by the ChIP assay (Fig. 2c and
d). The obtained results clearly showed that the com-
bination played an important role in the suppression of
binding activities.The MSM-tamoxifen combination synergistically inhibited
downstream targets of the STAT5b pathway
In the previous section, we found that the MSM-Tam
combination synergistically inhibited the STAT5b-DNA
binding properties. This inhibition of the DNA binding
activities of STAT5b should result in impaired transcrip-
tion promoter functions. In order to confirm this, the ex-
pression of STAT5b downstream targets was analyzed at
both the transcriptional (Fig. 3c and d) and translational
(Fig. 3a and b) levels. In both cell lines, the expression of
cyclin D1, VEGF, IGF-1, and IGF-1Rβ were found to decline
in the combination-treated samples (Fig. 3).
The combination of MSM and tamoxifen synergistically
inhibited invasion and migration through STAT5b
The inhibition of invasion was studied using a Matrigel
invasion assay (Fig. 4a). A relatively high level of
Fig. 3 The MSM-Tam combination synergistically inhibited the downstream targets of the STAT5b pathway. (a) Western blotting analysis
showing total protein levels of the downstream targets of STAT5b following treatment with the drug combination in MCF-7 and T47D cells. (b)
Graphical analysis of the action of the drug combination and the individual agents on the downstream targets of STAT5b in cytoplasmic proteins.
(c) RT-PCR analysis of RNA levels of downstream targets of STAT5b after the treatment with Tam, MSM, and the drug combination for 24 h in
MCF-7 and T47D cells. (d) Inhibition of RNA levels by the drug combination, Tam, and MSM relative to the percentage of 18 s RNA
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cells as compared to those treated with the individual
drug concentrations (Fig. 4b, P < 0.01 and P < 0.001). In
order to determine the role of STAT5b in invasion, we
silenced STAT5b using specific siSTAT5b in T47D cells.
Following the silencing of STAT5b, we analyzed the inva-
sion using a Matrigel invasion assay. The obtained result
provided strong proof for the role of STAT5b in invasion
(Fig. 4c). The use of non-target siRNA showed similar ex-
pression levels to those from non-siRNA treated controls.
Silenced STAT5b showed a significant invasion inhibition
as compared with the non-target group (Fig. 4d). Inhib-
ition of cell migration was determined by an in vitro
wound healing assay (Fig. 5a). The area of wound closure
was quantified using ImageJ software25, and the relative
inhibition of migration was determined. The results
showed a statistically significant inhibition of migration
in the combination-treated cells (Fig. 5b, P < 0.05 and
P < 0.01). MMPs are the major mediators of invasion
via digestion of the extracellular membrane, which
allows for cancer cells to enter the circulation [37].Hence, an inhibition in MMP expression should lead
to the inhibition of invasion. Our drug combination
exerted a synergistic inhibition of MMP2, MMP3, and
MMP9 at both the transcriptional and translational levels
(Fig. 5c and e). Densitometric analysis of MMPs proved
the capability of our drug combination to inhibit invasion
(Fig. 5d and f).
A combination of tamoxifen and MSM inhibited tumor
growth
The in vivo tumor suppressor activity of the drug combin-
ation was evaluated in Balb/c nude mice bearing breast tu-
mors induced by MCF-7 cells. After the formation of
palpable tumors, mice were treated with the individual
drugs and their combination. We observed a statistically
significant reduction in tumor volume (Fig. 6c, P < 0.001).
The drug combination resulted in a comparatively higher
inhibition of tumor growth. The toxicity of the drugs, as ev-
idenced by changes in the weight of the mice, was assessed,
and results showed that MSM and the combination
treatment had little or no side effects, as there was no
Fig. 4 The combination of MSM and Tam synergistically inhibited invasion through STAT5b. (a) A Matrigel invasion assay showing the invasion
inhibition of Tam, MSM, and the drug combination for 24 h in MCF-7 cells. (b) Graphical representation of the invasion assay results. (c) On-target
inhibition of STAT5b inhibited the invasion in T47D cells. (d) Graphical representation of the relative inhibition of invasion after silencing of STAT5b.
Statistical analyses were conducted using the ANOVA test (**P < 0.01 and ***P < 0.001)
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treated mice showed a slight decrease in weight (Fig. 6b).
The mice were then sacrificed and the xenografts excised
for further analysis. Morphological analysis using H&E
staining showed a relatively high degree of cell death in
the combination treated group (Fig. 6a).
Inhibition of pulmonary metastasis by the combination of
tamoxifen and MSM in vivo
The in vitro analysis revealed that the drug combination
had the ability to inhibit the epithelial-mesenchymal
transition, as well as the expression of MMPs. Therefore,
the ability of the combination to inhibit pulmonary me-
tastasis was analyzed using metastatic animal models.
The relative pulmonary metastasis was studied using
the lungs excised from the orthotopic animal models
(Fig. 7a). The relative metastatic area was detected and
plotted with respect to the percentage of metastasis in
the controls. Results showed a statistically significant pre-
vention of metastasis by the drug combination (Fig. 7b,
P < 0.01 and P < 0.001). The molecular targets for the
prevention of pulmonary metastasis were validated
in vivo using western blotting (Fig. 7c and d). Theseresults showed that the combination inhibited VEGF
and VEGF-R2 (responsible for angiogenesis) and MMP2,
MMP3, and MMP9 (responsible for invasion).
Administration of the MSM and tamoxifen combination
down-regulated the STAT5b/IGF-1Rβ signaling pathway
In order to elucidate the molecular mechanism by which
the drug combination inhibited tumor growth, analyses
were performed on xenografts. In theory, the drug combin-
ation could have had the capacity to inhibit phosphoryl-
ation and activation of STAT5b, and thereby the expression
of IGF-1Rβ. The immunofluorescence results showed that
treatment with Tam, MSM, and the combination decreased
the expression of STAT5b and IGF-1Rβ in the MCF-7
xenograft model without any alteration at the level of
the nucleus (Fig. 8a). The western blotting analyses of the
tissue protein extracts were concurrent with our previous
findings. Additionally, Jak2 and STAT3 were analyzed to
assess the involvement of these molecules in tumor growth
suppression. Study results clearly demonstrated that the
drug combination significantly suppressed the expression
and phosphorylation of Jak2, STAT5b, STAT3, and IGF-
1Rβ (Fig. 8b and c).
Fig. 5 The combination of MSM and Tam synergistically inhibited migration and matrix metalloproteinases. (a) A wound healing assay showing
the migration inhibition of MCF-7 cells treated with the drug combination and the individual agents for 24 h. (b) Relative inhibition of migration
in MCF-7 cells as per the wound healing assay. Statistical analyses were conducted using t-tests (*P < 0.05 and **P < 0.01). (c) RT-PCR analysis of
RNA levels of matrix metaloproteins after treatment with Tam, MSM, or the drug combination for 24 h in MCF-7 cells. (d) Graphical representation
of RNA levels of matrix metaloproteins after treatment with Tam, MSM, or the drug combination for 24 h in MCF-7 cells. (e) Western blot analysis
showing the levels of matrix metaloproteins in whole cell lysates following treatment with Tam, MSM, or their combination in MCF-7 cells. (f) Graphical
representation of matrix metaloproteins in whole cell lysates following treatment with Tam, MSM, or their combination in MCF-7 cells
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Conventional therapies do not usually have a specific
target. Instead, they work via the mass killing of cells,
which usually results in severe side effects. The advent
of combination therapies represents an experimental
breakthrough in the use of targeted therapies. A combin-
ation of two drugs for the treatment of cancer aims
mainly for the reduction of individual drug concentra-
tions while enhancing therapeutic effects. Such combin-
ation therapies are multi-targeted and have been shown
to be safe and effective in humans.
Tam is well known for its anti-BCa activities by target-
ing estrogen receptor [38]. The mechanistic role of Tam
has been confirmed as the modulation of the STAT5b/
IGF-1R pathway, as it acts as an inhibitor of IGF-1, IGF-
1Rβ, and STAT5b [39]. However, usage of Tam leads tovarious critical adverse effects [40]. As such, a great deal
of research has been conducted in order to reduce the
side effects associated with Tam without reducing its
efficacy. Tam used in combination therapy with many
other constituents for the treatment of breast cancer
[41–43]. It also synergize other drugs in the combination
therapy [44, 45] MSM is a natural sulfur containing
compound which acts against various breast cancers
[10, 27, 28] and is already found as an efficient drug in
combination therapy against cancer cells [46]. Combination
therapy is one of the methods we can employ to reduce
the adverse effects of the drug, either by reducing the
concentration of the individual drug, or by synergising
the mechanism of the drug. The dosage of MSM we
used in this study is a higher concentration. It is not the
amount of MSM that contains in food. We used a
Fig. 6 The combination of Tam and MSM inhibited tumor growth. (a) Panel 1 represents the xenograft model showing the tumor size obtained
following treatment with Tam, MSM, or the drug combination. Panel 2 represents the morphological analysis of tumors by H&E staining. (b)
Body weight analysis for drug-treated and vehicle-treated mice for a period of 30 days. (c) Graphical representation of the tumor size analysis for
vehicle-treated controls, and Tam, MSM, or drug combination-treated mice during 30 days of treatment. Statistical analyses were conducted using
the ANOVA test (***P < 0.001)
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tion) just for pharmacological purpose. In order to check
the efficacy of combination therapy, we reduced the con-
centrations of both MSM (200 mM) and Tam (15 μM).
Treatment with Tam may cause joint pain to the pateients,
whereas MSM is an effective drug for the treatment of
joint pain. So the usage of this drug combination may also
reduce the joint pain caused by Tam.
The proliferation inhibition ability of the drug combin-
ation was determined by an MTT assay (Fig. 1a). The
results showed that the different combinations made
from Tam and MSM had different degrees of prolifera-
tion inhibition ability. The synergistic combination of
these two agents was formulated with the help of a
Compusyn-based computer simulation (Additional file 1:
Table S1). Tis simulation showed that the ratios of
1:10000 and 3:40000 had the ability to inhibit BCa cell
proliferation in a synergistic manner. Ideally, anticancer
drugs should mediate a maximal rate of cell growth
regulation. Hence, we opted to use the ratio of 3:40000
as the synergistic combination for further experiments.The results for apoptosis induction showed that the
combination had the ability to induce a maximal rate of
apoptosis as compared to the individual agents (Fig. 1c).
This was confirmed by DNA strand breaks, which are a
hallmark of apoptotic cell death (Additional file 2:
Figure S1). Furthermore, the expression of Bax is re-
lated to the induction of apoptosis in cells [47]. We
observed an increase in the expression of Bax proteins
in both the MCF-7 and T47D cells exposed to the com-
bination therapy (Fig. 1d and e), indicating the ability of
our drug combination to induce apoptosis.
Jak2 is a receptor kinase known to play a vital role
in the Jak2/STAT5b signaling pathway, as activation of
Jak2 regulates the activity of downstream molecules in
the pathway [48]. Therefore, blockage of Jak2 leads to
the blockage of the Jak2/STAT5b pathway. Treatment
with the drug combination inhibited Jak2 protein levels
in vitro and in vivo, as well as their phosporylation
(Fig. 2a and 8b). STAT5b is the primary substrate of
Jak2 [49], which is important in BCa management and
takes part in growth hormone signaling. It is a transcription
Fig. 7 Inhibition of pulmonary metastasis by the combination of Tam and MSM in vivo. (a) A metastatic animal model showing the pulmonary
metastasis analysis for the Tam, MSM, drug combination-treated, or vehicle-treated controls. (b) Graphical representation of pulmonary metastasis
following treatment with Tam, MSM, or the drug combination with respect to percentage of the control. Statistical analyses were conducted using the
ANOVA test (**P < 0.01 and ***P < 0.001). (c) Tissue protein analysis of various matrix metaloproteins and angiogenic factors after the treatment with
Tam, MSM, or the drug combination for 24 h using western blotting. (d) Graphical analysis of different tissue proteins following exposure to Tam, MSM,
or the drug combination
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considered as a key regulator of tumorigenesis [50].
STAT5b mediates the transcription of numerous genes
and is involved in many functions, such as cellular prolif-
eration, differentiation [51, 52], survival [53], cell cycle
regulation [54], migration, invasion, and metastasis [55].
We confirmed that the expression of STAT5b and
phospho-STAT5 was inhibited by the drug combination at
both the cytoplasmic and nuclear levels (Fig. 2a and c).
IGF-1Rβ is highly expressed in BCa [56]. We observed
a decrease in IGF-1Rβ at both the cytoplasmic and
nuclear levels in cells, as well as in vivo when exposed to
combination therapy (Fig. 8b). The decrease in IGF-1Rβ
can be correlated with the inhibition of DNA binding
activity found in the drug combination-treated cells
(Fig. 2c and d). The DNA binding of STAT5b is essential
for the transcription of downstream targets including
IGF-1Rβ [57]. Furthermore, IGF-1Rβ plays important
roles in different functions, such as tumor invasion, me-
tastasis [58], and cell death and growth functions [59].
The results of a recent study demonstrated that theinhibition of STAT5b led to a decline in the expression of
IGF-1Rβ in BCa cells [10]. This suggests that IGF-1Rβ
may be in proportion with STAT5b such that regulation of
these molecules is interdependent. Our drug combination
showed similar responses for STAT5b and IGF-1Rβ
expression. Both transcriptional and translational level
inhibition of IGF-1Rβ was observed in cells exposed to
the synergistic drug combination. These results were
also confirmed in vivo. The xenograft model demmon-
strated a significant decrease in IGF-1Rβ (Fig. 8a). Both
IGF-1Rβ and its phosphorylated form were more reduced
by the action of the drug combination than by either of the
individual agents alone.
In previous studies, we reporteded that STAT3 was
found to be overexpressed in many tumors, especially in
BCa [10, 60]. Furthermore, it was shown to have direct
associations with many cellular process, such as apop-
tosis inhibition [61], enhancement of angiogenesis [62],
and increasing of metastasis [63]. The obtained results
suggested that MSM synergized the activity of Tam in
the drug combination by inhibiting the STAT3 molecule
Fig. 8 Exposure to the MSM-Tam combination downregulated the STAT5b/IGF-1Rβ signaling pathway. (a) Immunofluorescence analysis of
STAT5b and IGF-1Rβ showing the inhibition ability of the drug combination. (b) Western blotting analysis of various tissue protein levels after
treatment with the drug combination or the individual agents for 24 h. (c) Relative expression of tissue protein levels following exposure to Tam,
MSM, or their combination
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Nuclear translocation of STAT3 was also found to be
decreased by the combination therapy. VEGF is an im-
portant downstream target of STAT3 [64], which is
involved in the metastasis of BCa via increased angio-
genesis [65]. The effective inhibition was found in the
expression levels of VEGF and its receptor (VEGF-R2)
both in vitro and in vivo after the treatment with drug
combination (Fig. 3c and 7c).
The molecular validation of the in vitro analysis
showed that the combination had the capacity to pre-
vent tumor growth by regulating STAT5b-IGF-1Rβ in-
hibition and by inhibiting metastasis via regulation of
the expression of VEGF, VEGF-R2, and the MMPs. This
ability was confirmed in vivo by BCa xenograft and
metastatic animal models. The primary tumor induced
in Balb/c athymic nude mice showed a significant de-
crease in tumor growth in combination-treated animals.Toxicity of the drug and the tumor burden were
observed by monitoring dietary habits and body weight
gain. The results showed a slight decrease in body
weight in Tam-treated animals, while body weight
remained unaltered or slightly elevated in all other
groups (Fig. 6b). The tumor suppression ability of
the drugs was measured by monitoring the volume of
tumor. The drug combination provided a statistically
significant result after a treatment period of 30 days
(Fig. 6c, P < 0.001).
Metastasis is a crucial cause of the mortality in cancer
[66], and cell migration and invasion are important steps
in metastasis [67]. Hence, inhibition in migration and
invasion determines the ability to hinder metastasis.
Our drug combination showed a statistically significant
inhibition of migration and invasion (Fig. 4b and 5b) as
compared to its individual agents. We also proved that
STAT5b was the key factor for invasion, and thereby
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a statistically significant inhibition in invasion, which
demonstrated the role of STAT5b in cell migration and
invasion. In order to confirm this, we analyzed the
expression levels of MMPs which plays a vital role in
cancer metastasis [68–70]. Among MMPs, MMP2 and
MMP9 were found to be overexpressed and mediated
higher rates of invasion and metastasis in various types
of cancers [71–74]. The combination of MSM and Tam
inhibited the expression of MMPs in vitro and in vivo
(Fig. 4b and 7c). The expression levels of MMPs and
VEGF were down-regulated by drug combination which
may be due to the higher rate of apoptosis induction
by the combination. But the inhibition of migration,
invasion and pulmonary metastasis proved the capability
of the drug combination, eventhough it is a weakness of
the work in case of animal model. These molecules were
downregulated by the action of combination therapy at
both the protein and RNA levels (Fig. 5c and d). These
results suggest the ability of the drug combination to
inhibit migration and invasion, and thereby metastasis.
Inhibition of metastasis was confirmed in the metastatic
animal model. A significant inhibition of pulmonary
metastasis was obtained using the drug combination
(Fig. 7a). Only 6 % of all metastases observed was found in
the drug combination-treated group (Fig. 7b).Conclusions
The results of the current study demonstrated that our
drug combination synergistically inhibited the Jak2/
STAT5b signaling pathway and also inhibited BCa
growth and metastasis, even though the concentrations
of the drugs were lower as compared to the individual
agents. Therefore, the combination of Tam and MSM
may enhance therapeutic efficacy in the treatment of
human breast adenocarcinoma. The treatment combin-
ation had the added advantage of reducing the dose in-
tensity of the individual drugs, thereby reducing the
ocurrence and severity of the adverse effects associated
with the use of the individual drugs.Additional files
Additional file 1: Table S1. Dose-effect relationships of Tam, MSM and
their combinations on growth inhibition of MCF-7 breast adenocarcinoma
cells during 24 hours exposure. The parameters Dm, m and r are the slope,
antilog of r-intercept, and the linear correlation coefficient of the median-
effect plot, which signifies the potency (IC50), the shape of the dose-effect
curve, and conformity of the data to the mass-action law, respectively. Dm
and m values are used for calculating the CI values. CI < 1, CI =1, and CI > 1
indicate synergism, additivity, and antagonism, respectively. As based
on the classic isobologram equation, CI can be calculated by CI = [(D)1/
(Dx)1] + [(D)2/(Dx)2], where Dx = Dm[fa/(1 - fa)]
1/m. The combination ratio
was approximately equal to the Dm ratio of the component drugs
(i.e., close to their equipotency ratio).Additional file 2: Figure S1. The combination of Tam and MSM
induced apoptosis in ER+ breast cancer cells. DNA fragmentation assay
showing the ladder formation upon treatment with Tam, MSM,
and their combination for 24 h. U937 cells induced apoptosis with
camptothecin and were used as positive control.
Additional file 3: Figure S2. (a) Densitometrial analysis of cytoplasmic
protein levels in MCF-7 and T47D cells, and after treatment with Tam,
MSM, or their combination for 24 h. (b) Graphical representation of nuclear
protein level analysis in MCF-7 and T47D cells, and after treatment with Tam,
MSM, or the drug combination for 24 h.
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